Nov 08, 2025

Today, I came across news about Tesla’s upcoming shareholder meeting, where shareholders will vote on Elon Musk’s new $1 trillion stock compensation package. If approved, this package could potentially turn Tesla into an $8.5 trillion company over the next decade. However, if not approved, Musk might leave the company, impacting its value significantly. Shareholders are facing a tough decision, as rejecting the proposal could be seen as a negative sign on Musk’s leadership.

There is also concern about bond market liquidity, with the traditional system of dealers intermediating bond trades facing challenges. MarketAxess Holdings Inc. is looking to introduce a daily “closing print” for corporate bonds to improve transparency and liquidity. Additionally, private markets are gaining popularity, with Charles Schwab acquiring Forge Global to provide investors access to private investments.

In the crypto space, the trend of crypto treasury companies, where public companies hold cryptocurrency, is facing pressure as the value of tokens held by these firms is decreasing. Companies like Metaplanet Inc. and ETHZilla are selling crypto to buy back shares due to market conditions. Lastly, a former FDA official, Dr. George Tidmarsh, is facing a lawsuit from a pharmaceutical company accusing him of false statements and soliciting a bribe, highlighting potential issues of personal vendettas influencing regulatory decisions.

Overall, these developments in the financial and regulatory sectors showcase the complexities and challenges faced by investors, companies, and regulatory bodies. From key decisions impacting shareholder value to shifts in market dynamics and potential conflicts of interest in regulatory actions, the financial landscape continues to evolve, requiring careful consideration and analysis for all stakeholders involved.

I recently learned about a legal battle involving Aurinia Pharmaceuticals and Dr. Tidmarsh, the former CEO of La Jolla Pharmaceutical Co. Tidmarsh, who now serves as Chair of the Board of Aurinia, allegedly made defamatory statements about Tang Capital Partners, Aurinia’s largest shareholder. The situation escalated when Tidmarsh, while working at the FDA, posted negative comments about drugs produced by companies affiliated with Tang, causing Aurinia’s stock to decline temporarily.

Stay Well!